Table 4.
Serum Clinical Chemistry Markers
| 300 mg | 600 mg | |||||||||
| Week | 0 | 1 | 3 | 8 | 11 | 0 | 1 | 3 | 8 | 11 |
| Triglyceride (mg/dl) | 86.8 ± 29.5 | 98.5 ± 46.1 | 105.3 ± 29.5 | 110.3 ± 58.8 | 85.9 ± 41.9 | 117.5 ± 60.2 | 115.5 ± 50.5 | 116.6 ± 40.5 | 110.9 ± 43.4 | 97.8 ± 36.1 |
| Cholesterol (mg/dl) | 177.0 ± 38.2 | 182.1 ± 26.1 | 173.9 ± 32.2 | 175.0 ± 22.6 | 166.1 ± 20.7 | 194.6 ± 24.9* | 185.1 ± 22.3* | 201.1 ± 20.8* | 201.6 ± 37.8* | 199.5 ± 31.0* |
| HDL (mg/dL) | 50.1 ± 12.5 | 51.3 ± 10.9 | 53.6 ± 17.6 | 49.4 ± 7.9 | 48.3 ± 8.9 | 53.0 ± 4.7 | 53.8 ± 9.8 | 58.5 ± 11.9 | 53.9 ± 18.7 | 57.0 ± 18.3 |
| LDL (mg/dL) | 107.9 ± 26.9 | 112.0 ± 18.8 | 105.4 ± 23.5 | 104.4 ± 22.8 | 100.6 ± 16.8 | 115.9 ± 21.5* | 111.4 ± 21.7* | 124.8 ± 22.0* | 127.1 ± 33.5* | 121.4 ± 25.2* |
| GGT (U/L) | 23.9 ± 5.7 | 23.8 ± 4.6 | 23.1 ± 4.8 | 27.3 ± 7.9 | 26.0 ± 7.0 | 32.3 ± 9.6* | 33.6 ± 11.2* | 33.6 ± 7.8* | 38.8 ± 11.8* | 36.4 ± 8.3* |
| LDH (U/L) | 127.0 ± 19.4 | 130.6 ± 23.3 | 125.4 ± 19.6 | 114.5 ± 25.8 | 130.0 ± 33.0 | 125.5 ± 17.4 | 128.0 ± 18.0 | 132.8 ± 23.4 | 132.1 ± 24.6 | 140.6 ± 32.6 |
| Uric Acid (g/dl) | 6.1 ± 1.7 | 5.8 ± 1.1 | 5.7 ± 0.9 | 5.2 ± 1.0 | 5.5 ± 1.4 | 6.1 ± 1.3 | 6.1 ± 1.6 | 6.5 ± 1.2 | 5.7 ± 1.0 | 5.7 ± 1.3 |
| Glucose mg/dl | 94.5 ± 9.4 | 95.8 ± 10.3 | 97.6 ± 10.4 | 94.0 ± 8.2 | 93.9 ± 9.6 | 95.1 ± 8.4 | 94.3 ± 6.5 | 100.5 ± 6.1 | 105.1 ± 17.1 | 89.9 ± 14.8 |
| BUN (mg/dL) | 16.9 ± 2.9 | 19.4 ± 5.0 | 20.6 ± 4.5 | 18.5 ± 3.0 | 19.4 ± 3.6 | 21.1 ± 7.6* | 22.3 ± 5.1* | 22.5 ± 3.8* | 19.8 ± 3.5* | 21.3 ± 2.4* |
| Creatinine (mg/dl) | 1.4 ± 0.1 | 1.4 ± 0.2 | 1.4 ± 0.2 | 1.3 ± 0.2 | 1.3 ± 0.3 | 1.4 ± 0.2 | 1.4 ± 0.2 | 1.5 ± 0.2 | 1.5 ± 0.2 | 1.3 ± 0.3 |
| Calcium (mg/dl) | 12.5 ± 1.7 | 14.2 ± 3.2 | 14.8 ± 3.0 | 14.9 ± 2.1 | 15.2 ± 3.4 | 15.6 ± 4.4* | 16.4 ± 3.4* | 14.9 ± 2.8* | 13.7 ± 2.6* | 17.0 ± 3.0* |
| Total Protein g/dL | 9.8 ± 0.5 | 9.9 ± 0.4 | 9.9 ± 0.6 | 9.8 ± 0.5 | 9.5 ± 0.4 | 10.1 ± 0.6* | 10.1 ± 0.7* | 10.8 ± 0.7* | 10.4 ± 0.7* | 10.2 ± 0.9* |
| Albumin g/dL | 7.4 ± 0.6 | 7.7 ± 0.4 | 7.8 ± 0.6 | 7.4 ± 0.5 | 7.3 ± 0.5 | 7.9 ± 0.9* | 8.0 ± 0.9* | 8.5 ± 1.0* | 8.3 ± 0.9* | 8.1 ± 0.9* |
| Total Bilirubin (mg/dl) | 4.7 ± 0.5 | 4.8 ± 0.4 | 4.9 ± 0.5 | 4.6 ± 0.5 | 4.6 ± 0.3 | 5.0 ± 0.5 | 5.1 ± 0.5 | 5.4 ± 0.6 | 5.3 ± 0.6 | 5.1 ± 0.6 |
| ALP (U/L) | 0.8 ± 0.3 | 0.8 ± 0.6 | 1.0 ± 0.4 | 0.9 ± 0.5 | 0.9 ± 0.6 | 0.6 ± 0.3 | 0.6 ± 0.2 | 0.9 ± 0.4 | 0.8 ± 0.3 | 0.8 ± 0.2 |
| AST (U/L) | 73.9 ± 13.3 | 76.3 ± 12.1 | 73.1 ± 12.8 | 70.5 ± 15.7 | 64.0 ± 19.9 | 77.1 ± 21.3 | 76.1 ± 21.0 | 79.5 ± 19.4 | 76.4 ± 19.0 | 63.1 ± 27.8 |
| ALT (U/L) | 24.4 ± 9.6 | 24.5 ± 9.3 | 21.3 ± 6.8 | 18.3 ± 6.6 | 30.3 ± 25.1 | 22.6 ± 6.5 | 27.3 ± 5.5 | 30.0 ± 11.7 | 24.5 ± 8.0 | 26.3 ± 10.0 |
| CK (U/L) | 28.6 ± 11.5 | 25.6 ± 5.5 | 22.4 ± 7.2 | 28.4 ± 10.8 | 27.1 ± 5.5 | 28.1 ± 14.2 | 25.0 ± 7.2 | 23.8 ± 6.7 | 28.9 ± 15.6 | 32.6 ± 10.7 |
* Denotes significant main effects for groups (p < 0.05) indicating that the 600 mg group had higher baselines that persisted throughout the study, and was apparently independent of 6-OXO supplementation.